Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-13
2010-11-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S295000, C544S360000, C544S383000, C514S253010, C514S255030
Reexamination Certificate
active
07825122
ABSTRACT:
Diaza heterocyclic sulfonamide derivatives according to formula I have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:where R7, R8, R9, R10, R11, R12, R13, X, Y1, Y2, m, and n are set forth in the description.
REFERENCES:
patent: 4159331 (1979-06-01), McCall
patent: 5138058 (1992-08-01), Geisen et al.
patent: 6403595 (2002-06-01), Tawada et al.
patent: 6492368 (2002-12-01), Dorsch et al.
patent: 6680312 (2004-01-01), Tawada et al.
patent: 6683093 (2004-01-01), Barta et al.
patent: 6720338 (2004-04-01), Augeri et al.
patent: 6750228 (2004-06-01), Barta et al.
patent: 2005/0234046 (2005-10-01), Zhao et al.
patent: 1510032 (2004-07-01), None
patent: 2706459 (1993-06-01), None
patent: 2001261657 (2001-09-01), None
patent: 2001261657 (2001-09-01), None
patent: WO 93/12086 (1993-06-01), None
patent: WO 94/04505 (1994-03-01), None
patent: WO 9608495 (1996-03-01), None
patent: WO 97/28128 (1997-08-01), None
patent: WO 97/28129 (1997-08-01), None
patent: WO 97/40049 (1997-10-01), None
patent: WO 99/67244 (1999-12-01), None
patent: WO 00/17163 (2000-03-01), None
patent: WO 00/32599 (2000-06-01), None
patent: WO 00/59510 (2000-10-01), None
patent: WO 00/69821 (2000-11-01), None
patent: WO 01/36408 (2001-05-01), None
patent: WO 02/24636 (2002-03-01), None
patent: WO 02/085885 (2002-10-01), None
patent: WO 03/040096 (2003-05-01), None
patent: WO 03/076422 (2003-09-01), None
patent: WO 03/082288 (2003-10-01), None
patent: WO 03/082873 (2003-10-01), None
patent: WO 2004/018414 (2004-03-01), None
patent: WO 2004/033436 (2004-04-01), None
patent: WO 2004/037251 (2004-05-01), None
patent: WO 2004/058732 (2004-07-01), None
patent: WO 2004/065539 (2004-08-01), None
patent: WO 2004/092117 (2004-10-01), None
patent: WO 2004/092123 (2004-10-01), None
patent: WO 2005/030770 (2005-04-01), None
patent: WO 2005/063247 (2005-07-01), None
patent: WO 2005/113542 (2005-12-01), None
patent: WO 2005/115983 (2005-12-01), None
patent: WO 2005/118538 (2005-12-01), None
patent: WO 2006/105127 (2006-10-01), None
patent: WO 2007/070506 (2007-06-01), None
Abstract, Lorenzo Williams, Thin layer Chromatography as a tool for reaction optimization in Microwave assisted synthesis, Chemical Communications,(Cambridge) 2000, (6), pp. 435-436.
Alovero et al., “Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change its Primary Target in Streptococcus Pneumoniae from Topoisomerase IV to Gyrase,”Antimicrobial Agents and Chemotherapy, vol. 44, No. 2, American Society for Microbiology, Feb. 2000, pp. 320-325.
Alovero et al., “Comparative Study of New Benzenesulphonamide Fluoroquinolones Structurally Related to Ciprofloxacin Against Selected Ciprofloxacin-Susceptible and -Resistant Gram-Positive Cocci,”Journal of Antimicrobial Chemotherapy, vol. 48, No. 5, Oxford University Press, Nov. 2001, pp. 709-712.
Cui et al., “Synthesis and Antibacterial Activity of Oxazolidinone Containing Sulfonyl Group ”Bioorganic&Medicinal Chemistry Letters, vol. 13, No. 14, Elsevier Science B.V., 2003, pp. 2311-2313.
Fotsch et al., 11β-Hydroxysteroid Dehydrogenase-1 as a Therapeutic Target for Metabolic Diseases, Expert Opinion on Therapeutic Patents, vol. 15, No. 3, Mar. 1, 2005, pp. 289-303, Ashley Publications, GB (XP-002376609).
Keiser et al., “Evaluation of Quinolone Derivatives for Antitrypanosomal Activity,”Tropical Medicine&International Health, vol. 6, No. 5, Blackwell Science Ltd., May 2001, pp. 369-389.
Marrero-Ponce et al., “Atom, Atom-Type, and Total Nonstochastic and Stochastic Quadratic Fingerprints: a Promising Approach for Modeling of Antibacterial Activity,”Bioorganic&Medicinal Chemistry, vol. 13, No. 8, Elsevier Ltd., 2005, pp. 2881-2899.
McCall et al., “7-(Trifluoromethyl)-4-Aminoquinoline Hypotensives: Novel Peripheral Sympatholytics,”Journal of Medicinal Chemistry, vol. 29, No. 1, 1986, pp. 133-137.
Nieto et al., “A New Class of Fluoroquinolones: Benzenesulfonamidefluoroquinolones (BSFQs), Antibacterial Activity and SAR Studies,”European Journal of Medicinal Chemistry, vol. 34, No. 3, Editions Scientifiques Medicales Elsevier, 1999, pp. 209-214.
Nieto et al., “Hydrophobicity Estimations of Benzenesulfonamidofluoroquinolones (BSFQs) by RP-LC,”Medicinal Chemistry Research, vol. 12, No. 2, Birkhaeuser Boston, 2003, pp. 94-110.
Nieto et al., “Benzenesulfonamide Analogs of Fluoroquinolones,”European Journal of Medicinal Chemistry, vol. 40, No. 4, Elsevier Ltd., 2005, pp. 361-369.
Salvino et al., “Polymer-Supported Tetrafluorophenol: A New Activated Resin for Chemical Library Synthesis,”Journal of Combinatorial Chemistry, vol. 2, No. 6, American Chemical Society, Nov. 2000, pp. 691-697.
Powers Jay P.
Sun Daqing
Tu Hua
Yan Xuelei
Amgen Inc.
Foley & Lardner LLP
Sackey Ebenezer
Wilson James O
LandOfFree
Diaza heterocyclic sulfonamide derivatives and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaza heterocyclic sulfonamide derivatives and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaza heterocyclic sulfonamide derivatives and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241592